Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 3/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7205435 | 0.98 | NAMPT (0.46) | NAMPTPOLBTDP1KMT2AMEN1 | |
| SCHEMBL742552 | 0.90 | TDP1 (0.50) | NAMPTPOLBTDP1KMT2AMEN1 | |
| SCHEMBL29681728 | 0.88 | TDP1 (0.51) | POLBTDP1KMT2AMEN1ALDH1A1 | |
| SCHEMBL7995201 | 0.85 | CYP19A1 (0.46) | NAMPTPOLBCYP19A1LMNAALDH1A1 | |
| SCHEMBL935980 | 0.83 | TDP1 (0.59) | TDP1KMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL2672559 | 0.83 | MMP8 (0.54) | NAMPTKMT2ACYP19A1ALDH1A1L3MBTL1 | |
| SCHEMBL11276809 | 0.83 | MEN1 (0.59) | POLBTDP1KMT2AMEN1LMNA | |
| SCHEMBL8633006 | 0.81 | TDP1 (0.47) | TDP1KMT2AMAPK1L3MBTL1TSHR | |
| SCHEMBL10757869 | 0.81 | CYP4F2 (0.60) | POLBTDP1KMT2AMEN1ALDH1A1 | |
| SCHEMBL10755378 | 0.81 | CYP4F2 (0.47) | POLBTDP1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1236725-B1 | NOVEL 1,8-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | GRELAN PHARMACEUTICAL CO (JP) | 2004-03-10 | — | — | EP | disclosed |
| US-6642250-B2 | As phosphodiesterase inhibitor for prophylaxis and therapy of bronchial asthma; pneumonic diseases, pulmonary emphysema, chronic obstructive pulmonary disease acute respiratory distress syndrome (ARDS), and other respiratory diseases | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-0882712-B1 | PROCESS FOR PREPARING ACID SALTS OF GAMMA-(PIPERIDYL)BUTYRIC ACID | KOEI CHEMICAL CO (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-20030036651-A1 | Novel 1,8-naphthyridin-2(1h)-one derivatives | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 2003-02-20 | — | — | US | disclosed |
| EP-1030831-A4 | PROCESS FOR THE PREPARATION OF AZACYCLOALKYLALKANOYL PSEUDOTETRAPEPTIDES | AVENTIS PHARM PROD INC (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1236725-A1 | NOVEL 1,8-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | Grelan Pharmaceutical Co., Ltd. (JP) | 2002-09-04 | — | — | EP | disclosed |
| EP-0694546-B1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and use | SEARLE & CO (US) | 2001-06-06 | — | — | EP | disclosed |
| US-6197961-B1 | HYDROGENATION OF G-(PYRIDYL)BUTYRIC ACID SALT IN SOLVENT USING PALLADIUM, RHODIUM, OR RUTHENIUM CATALYST; HYDROLYSIS, DECARBOXYLATION | KOEI CHEMICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| US-6180759-B1 | PREPARING AZACYCLOALKANOYLPSEUDOTETRAPEPTIDES COMPRISING COUPLING A DIPEPTIDE WITH A PSEUDODIPEPTIDE; FOR EXAMPLE, N-(N-ETHYL-N-(1-OXO-4-(4-PIPERIDINYL)BUTYL)GLYCYL)-(L)-ALPHA-ASPARTYL-3 -CYCLOHEXYL-(L)-ALANINEAMIDE; USE AS ANTICOAGULANTS | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-01-30 | — | — | US | disclosed |
| EP-1030831-A1 | PROCESS FOR THE PREPARATION OF AZACYCLOALKYLALKANOYL PSEUDOTETRAPEPTIDES | Aventis Pharmaceuticals Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-0667850-B1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE FARMACEUTICI SPA (IT) | 1997-05-28 | — | — | EP | disclosed |
| US-5576315-A | Substituted dibenzoxazepine compounds and methods for treating osteoporosis and ischemia | G.D. SEARLE & CO. (US) | 1996-11-19 | — | — | US | disclosed |
| EP-0694545-A2 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1996-01-31 | — | — | EP | disclosed |
| EP-0694546-A2 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. SEARLE & CO. (US) | 1996-01-31 | — | — | EP | disclosed |
| US-5464830-A | ANALGESICS | G. D. SEARLE & CO. (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0667850-A1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS. | DOMPE FARMACEUTICI SPA (IT) | 1995-08-23 | — | — | EP | disclosed |
| US-5378840-A | Substituted dibenzoxazepine compounds | G. D. SEARLE & CO. (US) | 1995-01-03 | — | — | US | disclosed |
| WO-1994010127-A1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE' FARMACEUTICI S.P.A. (IT) | 1994-05-11 | — | — | WO | disclosed |
| WO-1992019617-A2 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0512400-A1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. Searle & Co. (US) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036651-A1 | Novel 1,8-naphthyridin-2(1h)-one derivatives | PDE3B, PDE4A, PDE4B | NAMPT 1018/4885POLB 691/4885TDP1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.